The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares findings from a first-in-human Phase I trial (NCT04775745) of the novel BTK inhibitor rocbrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Woyach highlights that the drug was well-tolerated with encouraging overall response rates. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
